The FINANCIAL — Xin Hee is publicly offering 106.6667 million shares, including 106.6667 million IPO shares offered at 8.99 yuan per share and raising funds of 959 million yuan. The post-public-offering share capital of Xin Hee is 426.6667 million in total. Xin Hee Co., Ltd. principally engages in design, production and sale of high-end women’s clothing. In 2019, its operating income reached 1,965 million yuan with the net profit of 242.223 million yuan.
Dayang Biotech is publicly offering 15 million shares, including 15 million IPO shares offered at 28.85 yuan per share and raising funds of 433 million yuan. The post-public-offering share capital of Dayang Biotech is 60 million in total. Zhejiang Dayang Biotech Group Co., Ltd. principally engages in production and sale of chemical raw materials such as inorganic salts and veterinary raw materials. In 2019, its operating income reached 622 million yuan with the net profit of 79.4972 million yuan.
Xin Hee (Stock Code: 003016) and Dayang Biotech (Stock Code: 003017) will land on SME Board on October 26, 2020.
